drugset / Trial / NCT05865002
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
NaSequentialOpen-labelTreatment
Summary
An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.
Timeline
- Start
- 2023-09-05
- Primary completion
- 2027-01
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AUR107 | Unknown | 5 mg | Oral |
| Subject | AUR107 | Unknown | 10 mg | Oral |
| Subject | AUR107 | Unknown | 20 mg | Oral |
| Subject | AUR107 | Unknown | 40 mg | Oral |
| Subject | AUR107 | Unknown | 60 mg | Oral |
| Subject | AUR107 | Unknown | 90 mg | Oral |
| Subject | AUR107 | Unknown | 135 mg | Oral |
| Subject | AUR107 | Unknown | 200 mg | Oral |